Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026
SHANGHAI and HONG KONG, Oct. 9, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class...
Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026
SHANGHAI and HONG KONG, Oct. 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class...
Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022
SHANGHAI and HONG KONG, Sept. 21, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class...
Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy
SHANGHAI and HONG KONG, Sept. 14, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class...
Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases
SHANGHAI and HONG KONG, Aug. 25, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class...
Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D
SHANGHAI and HONG KONG, Aug. 24, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class...
Antengene Announces Poster Presentation of ATG-022 and ATG-037 at ESMO 2026
SHANGHAI and HONG KONG, July 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class...
Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB
SHANGHAI and HONG KONG, July 13, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class...
On the Eve of BIO 2026, Chinese Innovative Assets Trigger a New Wave of Global Collaborations
SAN DIEGO, July 9, 2026 /PRNewswire/ -- On the eve of the highly anticipated BIO International Convention 2026, the BIOSeedin Summer Innovation Partnering Summit successfully took place in San Diego. Hosted by bioSeedin and proudly supported by...
Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
ATG-106 is a first-in-class CDH6 x CD3 bispecific T cell engager (TCE) in preclinical development for the treatment of solid tumors K2 Therapeutics, established by MPM BioImpact, obtains exclusive global rights to develop and commercialize ATG-106...